Cardiovascular Drugs and Therapy

Top Research Topics at Cardiovascular Drugs and Therapy?

The scientific interests tackled in Cardiovascular Drugs and Therapy are Internal medicine, Cardiology, Endocrinology, Anesthesia and Heart failure. Myocardial infarction, Blood pressure, Ischemia, Hemodynamics and Heart disease are all aspects of Internal medicine discussed in the journal. The journal is mostly focused on Myocardial infarction, specifically Percutaneous coronary intervention.

The Blood pressure works, particularly on Essential hypertension are tackled in the journal. Reperfusion injury and Cardioprotection are among the areas of Ischemia tackled. Vascular resistance is part of Hemodynamics studies tackled in it.

Studies on Cardiology discussed in the journal link to the field of Surgery. The studies tackled, which mainly focus on Endocrinology, apply to Pharmacology as well. Some problems in Anesthesia that were presented in Cardiovascular Drugs and Therapy overlapped with concepts under Nifedipine, Placebo and Heart rate.

• Internal medicine (67.01%)
• Cardiology (38.56%)
• Endocrinology (26.12%)

What are the most cited papers published in the journal?

• Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. (946 citations)
• Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. (529 citations)
• Anthracycline Chemotherapy and Cardiotoxicity (341 citations)

Research areas of the most cited articles at Cardiovascular Drugs and Therapy:

The journal articles focus on Internal medicine, Endocrinology, Cardiology, Pharmacology and Ischemia. The published papers facilitate discussions on Cardiology that incorporate concepts from other fields like Surgery and Blood pressure. The published articles explore research in Ischemia alongside concepts in Anesthesia and other areas of study in Angina and Heart rate.

What topics the last edition of the journal is best known for?

• Internal medicine
• Gene
• Enzyme

The previous edition focused in particular on these issues:

The objective of the journal is to combine knowledge in the areas of Internal medicine, Cardiology, Myocardial infarction, Pharmacology and Randomized controlled trial. The in-depth study on Internal medicine also explores topics in the intersecting field of Endocrinology. While the journal focused on Endocrinology, it was also able to explore topics like Cardiac function curve and Knockout mouse.

Cardiology research presented in it encompasses a variety of subjects, including Aspirin and Blood pressure. Concepts in Inflammation, as well as related topics in Cancer research, are covered in the Pharmacology research presented in Cardiovascular Drugs and Therapy. In it, Meta-analysis and Placebo are investigated in conjunction with one another to address concerns in Randomized controlled trial research.

The most cited articles from the last journal are:

• Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. (40 citations)
• Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. (13 citations)
• Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. (9 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Cardiovascular Drugs and Therapy (based on the number of publications) are:

• Derek M. Yellon (47 papers) absent at the last edition,
• Robert S. Rosenson (45 papers) published 5 papers at the last edition, 4 more than at the previous edition,
• Lionel H. Opie (43 papers) absent at the last edition,
• Willem J. Remme (33 papers) absent at the last edition,
• Roberto Ferrari (29 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Cardiovascular Drugs and Therapy (based on the number of publications) are:

• Baylor College of Medicine (60 papers) published 15 papers at the last edition, 6 more than at the previous edition,
• University of Cape Town (60 papers) published 1 paper at the last edition,
• Icahn School of Medicine at Mount Sinai (55 papers) published 8 papers at the last edition, 6 more than at the previous edition,
• University of Michigan (36 papers) published 5 papers at the last edition,
• Osaka University (35 papers) published 1 paper at the last edition, 1 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 2.71% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 15.81% were posted by at least one author from the top 10 institutions publishing in the journal. Another 14.42% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 10.23% of all publications and 59.53% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Qualifications and Licensing Requirements for Cardiovascular Nursing Professionals

While the journal provides an excellent resource for staying involved with the latest research and discussions in the field of cardiovascular healthcare, it is essential for readers to be aware of the prerequisites and skills expected in these professional roles. For those interested in pursuing a career in cardiovascular nursing, for instance, certain licensing requirements must be fulfilled. Some of these important requirements include foundational education in nursing, specialty training in cardiology, and obtaining licensure to practice.

In the United States, the licensing process and specifics may vary by state, mandating aspiring professionals to adhere to the guidelines set forth by respective state nursing boards. You may find interesting to take a look at some specifics of these requirements, for instance, the utah nursing license requirements provides a comprehensive look at the procedures, qualifications, and examinations required for a nursing license in Utah.

Observe how those requirements include successful completion of a state-approved nursing program, passing the National Council Licensure Examination for Registered Nurses (NCLEX-RN), and meeting continuing education requirements throughout the professional career. While these guidelines focus on Utah, similar standards exist in most states for practicing cardiovascular nursing.

This vital information can extend readers’ understanding of the practical aspects of a career in cardiovascular healthcare, supplementing the indispensable research insights presented in Cardiovascular Drugs and Therapy.